Cargando…

A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance

OBJECTIVE: To quantitatively determine the prevalence of anxiety and depression in men on active surveillance (AS). DESIGN: Cross-sectional questionnaire survey. SETTING: Secondary care prostate cancer (PCa) clinics across South, Central and Western England. PARTICIPANTS: 313 men from a total sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Watts, Sam, Leydon, Geraldine, Eyles, Caroline, Moore, Caroline M, Richardson, Alison, Birch, Brian, Prescott, Philip, Powell, Catrin, Lewith, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442147/
https://www.ncbi.nlm.nih.gov/pubmed/26002689
http://dx.doi.org/10.1136/bmjopen-2014-006674
_version_ 1782372863362203648
author Watts, Sam
Leydon, Geraldine
Eyles, Caroline
Moore, Caroline M
Richardson, Alison
Birch, Brian
Prescott, Philip
Powell, Catrin
Lewith, George
author_facet Watts, Sam
Leydon, Geraldine
Eyles, Caroline
Moore, Caroline M
Richardson, Alison
Birch, Brian
Prescott, Philip
Powell, Catrin
Lewith, George
author_sort Watts, Sam
collection PubMed
description OBJECTIVE: To quantitatively determine the prevalence of anxiety and depression in men on active surveillance (AS). DESIGN: Cross-sectional questionnaire survey. SETTING: Secondary care prostate cancer (PCa) clinics across South, Central and Western England. PARTICIPANTS: 313 men from a total sample of 426 with a histological diagnosis of PCa currently managed with AS were identified from seven UK urology departments. The mean age of respondents was 70 (51–86) years with the majority (76%) being married or in civil partnerships. 94% of responders were of white British ethnicity. PRIMARY OUTCOME MEASURES: The prevalence of clinically meaningful depression and anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS; score ≥8/21). SECONDARY OUTCOME MEASURES: Patient demographic data (age, employment, relationship, ethnic and educational status). Each demographic variable was cross-tabulated against patients identified as depressed or anxious to allow for the identification of variables that were significantly associated with depression and anxiety. In order to determine predictors for depression and anxiety among the demographic variables, logistic regression analyses were conducted, with p<0.05 considered as indicating statistical significance. RESULTS: The prevalence of clinical anxiety and depression as determined via the HADS (HADS ≥8) was 23% (n=73) and 12.5% (n=39), respectively. Published data from men in the general population of similar age has shown prevalence rates of 8% and 6%, respectively, indicating a twofold increase in depression and a threefold increase in anxiety among AS patients. Our findings also suggest that AS patients experience substantially greater levels of anxiety than patients with PCa treated radically. The only demographic predictor for anxiety or depression was divorce. CONCLUSIONS: Patients with PCa managed with AS experienced substantially higher rates of anxiety and depression than that expected in the general population. Strategies to address this are needed to improve the management of this population and their quality of life.
format Online
Article
Text
id pubmed-4442147
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44421472015-05-28 A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance Watts, Sam Leydon, Geraldine Eyles, Caroline Moore, Caroline M Richardson, Alison Birch, Brian Prescott, Philip Powell, Catrin Lewith, George BMJ Open Urology OBJECTIVE: To quantitatively determine the prevalence of anxiety and depression in men on active surveillance (AS). DESIGN: Cross-sectional questionnaire survey. SETTING: Secondary care prostate cancer (PCa) clinics across South, Central and Western England. PARTICIPANTS: 313 men from a total sample of 426 with a histological diagnosis of PCa currently managed with AS were identified from seven UK urology departments. The mean age of respondents was 70 (51–86) years with the majority (76%) being married or in civil partnerships. 94% of responders were of white British ethnicity. PRIMARY OUTCOME MEASURES: The prevalence of clinically meaningful depression and anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS; score ≥8/21). SECONDARY OUTCOME MEASURES: Patient demographic data (age, employment, relationship, ethnic and educational status). Each demographic variable was cross-tabulated against patients identified as depressed or anxious to allow for the identification of variables that were significantly associated with depression and anxiety. In order to determine predictors for depression and anxiety among the demographic variables, logistic regression analyses were conducted, with p<0.05 considered as indicating statistical significance. RESULTS: The prevalence of clinical anxiety and depression as determined via the HADS (HADS ≥8) was 23% (n=73) and 12.5% (n=39), respectively. Published data from men in the general population of similar age has shown prevalence rates of 8% and 6%, respectively, indicating a twofold increase in depression and a threefold increase in anxiety among AS patients. Our findings also suggest that AS patients experience substantially greater levels of anxiety than patients with PCa treated radically. The only demographic predictor for anxiety or depression was divorce. CONCLUSIONS: Patients with PCa managed with AS experienced substantially higher rates of anxiety and depression than that expected in the general population. Strategies to address this are needed to improve the management of this population and their quality of life. BMJ Publishing Group 2015-05-22 /pmc/articles/PMC4442147/ /pubmed/26002689 http://dx.doi.org/10.1136/bmjopen-2014-006674 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Urology
Watts, Sam
Leydon, Geraldine
Eyles, Caroline
Moore, Caroline M
Richardson, Alison
Birch, Brian
Prescott, Philip
Powell, Catrin
Lewith, George
A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title_full A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title_fullStr A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title_full_unstemmed A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title_short A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
title_sort quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance
topic Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442147/
https://www.ncbi.nlm.nih.gov/pubmed/26002689
http://dx.doi.org/10.1136/bmjopen-2014-006674
work_keys_str_mv AT wattssam aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT leydongeraldine aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT eylescaroline aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT moorecarolinem aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT richardsonalison aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT birchbrian aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT prescottphilip aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT powellcatrin aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT lewithgeorge aquantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT wattssam quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT leydongeraldine quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT eylescaroline quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT moorecarolinem quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT richardsonalison quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT birchbrian quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT prescottphilip quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT powellcatrin quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance
AT lewithgeorge quantitativeanalysisoftheprevalenceofclinicaldepressionandanxietyinpatientswithprostatecancerundergoingactivesurveillance